Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

Fig. 3

Association of hemoglobin with OS at baseline or 2–8 weeks after initiation of treatment. Cutoff of hemoglobin level to define anemia was 12 g/dL (a and b), the lower bound of reference range, or 10 g/dL (c and d), the definition of grade 2 or above adverse events according to NCI’s Common Terminology Criteria for Adverse Events (CTCAE)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us